Antiinflammatory effect of physical training in heart failure: Role of TNF-α and IL-10;Efeito antiinflamatório do treinamento físico na insuficiência cardíaca: Papel do TNF-a e da iL-10

Arquivos Brasileiros de Cardiologia

Volumn 93, Issue 6, 2009, Pages

  Júnior, Miguel Luiz Batista ^a   Lopes, Renato Delascio ^a,b   Seelaender, Marília Cerqueira Leite ^a   Lopes, Antonio Carlos ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Coronary artery disease; Exercise; Heart failure; Interleukins

Indexed keywords

CARDIOTROPHIN 1; CELL ADHESION MOLECULE; CHEMOATTRACTANT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ANTIINFLAMMATORY ACTIVITY; CHRONIC INFLAMMATION; DETERIORATION; DISEASE COURSE; DISEASE MARKER; EXERCISE; FLUID RETENTION; HEART FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; SODIUM RETENTION; TRAINING; KINESIOTHERAPY; METABOLISM; METHODOLOGY;

EXERCISE THERAPY; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950997670     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Sociedade Brasileira de Cardiología. Revisão das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagnóstico e tratamento da insuficiência cardíaca. Arq Bras Cardiol. 2002; 79: 1-30.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 2005; 112 (12): e154-235.
3. Larsen AI, Lindal S, Aukrust P Toft I, Aarsland T, Dickstein K. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. Int J Cardiol. 2002; 83 (1): 25-32.
4. Guimarães GV, Silva MSV, D'Avila VM, Ferreira SM, Silva CP Bocchi EA. VO2 pico e inclinação VE/VCO2 na era dos betabloqueadores na insuficiência cardíaca: uma experiência brasileira. Arq Bras Cardiol. 2008; 91: 42-48
5. Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail. 1999; 1 (4): 309-312
6. Yndestad A, Kristian Damås J, Øie E, Ueland T, Gullestad L, Alkrust P Systemic inflammation in heart failure - The whys and wherefores. Heart Fail Rev. 2006; 11 (1): 83-92.
7. Coats A, Clark A, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of lyfe in heart failure: the muscle hypothesis. Br Heart J. 1994; 72 (2 Suppl): S36-39.
8. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004; 90 (4): 464-470 (Pubitemid 38406929)
9. Candia AM, Villacorta Júnior H, Mesquita ET. Ativação imune-inflamatória na insuficiência cardíaca. Arq Bras Cardiol. 2007; 89: 201-208
10. Toth MJ, Ades PA, Tischler MD, Tracy RP, Lewinter MM. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol. 2006; 109 (2): 179-187
11. Gielen S, Adams V, Linke A, Erbs S, Mobius-Winkler S, Schubert A, et al. Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. Eur J Cardiovasc Prev Rehabil. 2005; 12 (4): 393-400.
12. Späte U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004; 7: 265-269
13. Gielen S, Walther C, Schuler G, Hambrecht R. Anti-inflammatory effects of physical exercise: a new mechanism to explain the benefits of cardiac rehabilitation? J Cardiopulm Rehab. 2005; 25 (6): 339-342
14. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond). 2003; 105 (1): 45-50.
15. Yamaoka M, Yamaguchi S, Okuyama M, Tomoike H. Anti-inflammatory cytokine profile i n human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. Jpn Circ J. 1999; 63 (12): 951-956
16. Waehre T, Halvorsen B, Damas JK, Yndestad A, Brosstad F, Gullestad L, et al. Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest. 2002; 32 (11): 803-810
17. Kaur K, Sharma A, Singal P Significance of changes in TNF-{alpha} and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol. 2006; 291 (1): H106-113.
18. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P Foody JM, et al. Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update: A Scientific Statement From the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2007; 115 (20): 2675-2682
19. Perk J, Veress G. Cardiac rehabilitation: applying exercise physiology in clinical practice. Eur J Appl Physiol. 2000; 83 (4): 457-462
20. Batista ML Jr, Santos RVT, Oliveira EM, Seelaender MC, Costa Rosa LF. Endurance training restores peritoneal macrophage function in post-MI congestive heart failure rats. J Appl Physiol. 2007; 102 (5): 2033-2039
21. Malefyt R. Interleukin-10. In: Mire-Sluis A, Thorpe R (eds.). Cytokines. 2nd ed. London: Academic Press; 1999. p. 151-161
22. Moore K, Malefyt R, Coffman R, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001; 19 (1): 683-765.
23. Beyaert R, Fiers W. Tumor necrosis factor and lymphotoxin. In: Mire-Sluis A, Thorpe R, (eds.). Cytokines. 2nd ed. London: Academic Press; 1999. p. 335-345
24. Shan K, Kurrelmeyer K, Seta Y, Wang F, Dibbs Z, Deswal A, et al. The role of cytokines in disease progression in heart failure. Curr Opin Cardiol. 1997;12 (3): 218-223
25. Anker S, Steinborn W, Strassburg S. Cardiac cachexia. Ann Med. 2004; 36 (7): 518-529
26. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol. 2000;72 (2): 175-186
27. Kang Y-M, Ma Y, Elks C, Zheng JP, Yang ZM, Francis J. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-{kappa}B. Cardiovasc Res. 2008; 79 (4):671-678
28. Zhang Z-H, Wei S-G, Francis J, Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol. 2003; 284 (4): R916-27.
29. Francis J, Wei S-G, Weiss RM, Felder RB. Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure. Am J Physiol Heart Circ Physiol. 2004; 287 (5): H2138-46.
30. Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail. 2001; 3 (5): 517-526
31. Figueras M, Busquets S, Carbó N, Almendro V, Argiles JM, Lopez-Soriano FJ. Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int J Oncol. 2005; 27 (3): 855-860
32. Aderka D, Engelmann H, Wysenbeek A, Levo Y. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr J Med Sci. 1992; 28 (2): 126-130
33. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor-{alpha} receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation. 2005; 111 (7): 863-870
34. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323 (4): 236-241
35. Anker SD, Coats AJS. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999; 115 (3): 836-847
36. Behnke BJ, Delp MD, McDonough P, Spier SA, Poole DC, Musch TI. Effects of chronic heart failure on microvascular oxygen exchange dynamics in muscles of contrasting fiber type. Cardiovasc Res. 2004; 61 (2): 325-332
37. Paulus W, Kastner S, Pujadas P, Shah AM, Drexler H, Vanderheyden M. Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft. Circulation. 1997; 96: 3436-3442
38. Ferrari R. Tumor necrosis factor in CHF: a double facet cytokine. Cardiovasc Res. 1998; 37 (3): 554-559
39. Anker SD, Rauchhaus M. Heart failure as a metabolic problem. Eur J Heart Fail. 1999; 1 (2): 127-131
40. Duscha BD, Annex BH, Green HJ, Pippen AM, Kraus WE. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll Cardiol. 2002; 39 (7): 1170-1174
41. Batista ML Jr, Santos R, Cunha LM, Mattos K, Oliveira EM, Seelaender MC, et al. Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. Cytokine. 2006; 34 (5-6): 284-290
42. Sasayama S, Matsumori A, Kihara Y New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res. 1999; 42 (3): 557-564
43. Gullestad L, Semb AG, Holt E, Skärdal R, Ueland T, Yndestad A. Effect of thalidomide in patients with chronic heart failure. Am Heart J. 2002; 144 (5): 847-850
44. Nozaki N, Yamaguchi S, Yamaoka M, Okuyama M, Nakamura H. Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure. J Moll Cell Cardiol. 1998; 30: 2003-2012
45. Bolger AP, Sharma R, von Haehling S, Doehner W, Oliver B, Rauchaus M, et al. Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. Am J Cardiol. 2002; 90 (4): 384-389
46. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999; 85 (8): e17-24.
47. Denys A, Udalova IA, Smith C, Williams LM, Ciesielski CJ, Campbell J, et al. Evidence for a dual mechanism for IL-10 suppression of TNF-{alpha} production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-{kappa}B in primary human macrophages. J Immunol. 2002; 168 (10): 4837-4845
48. Kaur K, Sharma AK, Dhingra S, Singra PK. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol. 2006; 41 (6): 1023-1030
49. Yu Y, Zhang Z-H, Wei S-G, Chu Y, Weiss RM, Heistad DD, et al. Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction. Circ Res. 2007; 101 (3): 304-312
50. Silva MSV, Bocchi EA, Guimarães GV, Padovani CR, Silva MN, Pereira SF. et al. Benefits of exercise training in the treatment of heart failure: study with a control group. Arq Bras Cardiol. 2002; 79: 351-362
51. Wisloff U, Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram PM, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation. 2007; 115 (24): 3086-3094
52. Carvalho RT, Vieira MLC, Romano A, Kopel L, Lage SG. Exercício resistido na avaliação da disfunção endotelial na insuficiência cardíaca. Arq Bras Cardiol. 2006; 86: 459-465
53. Niebauer J. Effects of exercise training on inflammatory markers in patients with heart failure. Heart Fail Rev. 2008; 13 (1): 39-49.
54. Adamopoulos S, Parissis J, Kroupis C, Georgiadis M, Karatzas D, Karavolias G, et al. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J. 2001; 22 (9): 791-797
55. Adamopoulos S, Parissis J, Karatzas D, Kroupis L, Georgiadis M, Karavolias G, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas/ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002; 39 (4): 653-663
56. Conraads VM, Beckers P, Bosmans J, De Clerck LS, Stevens WJ, Vrints CJ, et al. Combined endurance/resistance training reduces plasma TNF-{alpha} receptor levels in patients with chronic heart failure and coronary artery disease. Eur Heart J. 2002; 23 (23): 1854-1860
57. Costa Rosa LFBP, Batista Jr M. Efeito do treinamento físico como modulador positivo nas alteragoes no eixo neuroimunoendócrino em individuos com insuficiencia cardíaca crônica: Possível atuação do fator de necrose tumoral-α. Rev Bras Med Esporte. 2005; 11 (4): 238-242
58. Gielen S, Adams V, Mobius-Winkler S, Linke S, Erbs J, Yu W, et al. Antiinflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003; 42 (5): 861-868
59. Pedersen BK, Fischer CP Beneficial health effects of exercise - the role of IL-6 as a myokine. Trends Pharmacol Sci. 2007; 28 (4): 152-156
60. Petersen AMW Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005; 98 (4): 1154-1162
61. Fischer C, Berntsen A, Perstrup L, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports. 2007; 17 (5): 580-587
62. Flynn MG, McFarlin BK, Markofski MM. State of the art reviews: The anti- inflammatory actions of exercise training. Am J Lifestyle Med. 2007; 1 (3): 220-235
63. Fischer C. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev. 2006; 12: 6-33.
64. Starkie R, Ostrowski SR, Jauffred S, Febbraio MA, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-{alpha} production in humans. FASEB J. 2003; 17 (8): 884-886
65. Keller C, Keller P Giralt M, Hidalgo BK. Exercise normalises overexpression of TNF-alpha in knockout mice. Biochem Biophys Res Commun. 2004; 321 (1): 179-182 (Pubitemid 39055621)
66. Gullestad L, Kjekshus J, Damas JK, Ueland T, Yndestad A, Aukrust P. Agents targeting inflammation in heart failure. Expert Opinion on Investigational Drugs. 2005; 14 (5): 557-566
67. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357 (22): 2248-2261 (Pubitemid 350190755)
68. Spangenburg EE, Brown DA, Johnson MS, Moore RL. Exercise increases SOCS-3 expression in rat skeletal muscle: potential relationship to IL-6 expression. J Physiol. 2006; 572 (3): 839-848
69. Sriwijitkamol A, Christ-Roberts C, Berria R, Eagan P, Pratipanawatr T, DeFronzo RA,et al. Reduced skeletal muscle inhibitor of {kappa}B{beta} content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes. 2006; 55 (3): 760-767